Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 14Terminated 4Unknown 3Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

tremelimumab 4Cystoscopy 3durvalumab 2avelumab 2Paclitaxel 2Gemcitabine 2Docetaxel 2Cisplatin 2vocimagene amiretrorepvec 1vinflunine 1trebananib 1trastuzumab duocarmazine 1pegfilgrastim 1merphos 1infigratinib 1erdafitinib 1efineptakin alfa 1copanlisib 1atezolizumab 1Vinblastine 1Trastuzumab 1Taxes 1TAS-116 1Specimen Handling 1Sirolimus 1Rosiglitazone 1Ropivacaine 1Rogaratinib 1Radiotherapy 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Urinary Bladder Neoplasms × BCG Vaccine × Clear all
NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Bioniche Life Sciences Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡